Epcoritamab after BTK inhibitor for high-risk CLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies an investigational drug called epcoritamab, given after your usual treatment (a BTK inhibitor), to see if it can clear remaining CLL cells and reduce the chance of the cancer coming back. It's for people with CLL that has high-risk features, like genetic changes or resistance to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL) with at least one high-risk feature: you've had a prior treatment, you have a 17p deletion or TP53 mutation, or you have a complex set of chromosome changes.
- You have been taking a BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) for at least 6 months, and you can continue getting it.
- Tests show you still have some CLL cells in your blood or bone marrow (measurable residual disease, MRD).
- Your blood counts are within a safe range: lymphocyte count 10,000 or less, and no lymph node larger than 5 cm.
- Your organs (kidney, liver) and blood counts are working well, and you are physically active (can do daily activities).
- You do not have active disease in the brain or spinal cord, no serious immune-related blood cell issues, no current or past Richter's transformation, and no other active cancer that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
This study looks at how well a type of targeted therapy called a BTK inhibitor works for people with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. It includes both people who have never been treated and those whose cancer came back or didn't get better. The goal is to understand real-world outcomes and help guide future care.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Hear when a new CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.